Full Press Release Details
Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
Houston, Texas and Tuebingen, Germany, May 30,
2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"),
the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today
announced updated Phase 1 data for its IMA203CD8 PRAME TCR T-cell therapy in gynecologic cancers and synovial sarcoma at the Annual Meeting
of the American Society for Clinical Oncology (ASCO) in Chicago, IL, USA. One-time infusion of IMA203CD8 demonstrated meaningful clinical
activity across different tumor types as well as manageable tolerability. The broad expression of PRAME in more than 50 cancers further
supports the continued development of IMA203CD8 in multiple PRAME-positive solid tumors.
The updated Phase 1 results in gynecologic cancers
will be presented on May 30, 2026, during the Rapid Oral Abstract Session - Gynecologic Cancer from 8:00-9:30 am CDT by Antonia
Busse, M.D., Charit Medical University Hospital, Berlin, Germany (Abstract ID 5509). Presentation slides are accessible in the
Events & Presentations' section of the Investors & Media section of the Company's website. Phase 1 data in
synovial sarcoma will be presented on May 31, 2026, during the Rapid Oral Abstract Session - Sarcoma from 4:30-6:00 pm CDT by Dejka
M. Araujo M.D., The University of Texas MD Anderson Cancer Center (Abstract ID 11516). Presentation slides will be accessible on May 31,
"These clinical data in ovarian cancer, uterine
cancer and synovial sarcoma, along with previously released data in melanoma, further reinforce our aim to develop IMA203CD8 in PRAME-positive
cancers beyond melanoma. PRAME is expressed in more than 50 cancers, and the compelling anti-tumor activity observed in these historically
hard-to-treat indications supports its promise as a broadly applicable target," said Cedrik Britten, M.D., Ph.D., Chief Medical
Officer at Immatics. "We are encouraged by the consistency of response signals observed with IMA203CD8 and remain focused on advancing
IMA203CD8 in gynecologic cancers with the potential to broaden development to other indications in a tumor-agnostic approach to deliver
meaningful outcomes to patients."
Next development steps:
The clinical activity observed in ovarian cancer,
a tumor type generally associated with lower levels of PRAME expression, together with the observed activity across tumor types with different
and distinct tumor microenvironments, supports the broad applicability of IMA203CD8 across solid tumors with differing levels of PRAME
and tumor biology, starting with ovarian and uterine cancer. Updated data from the ongoing study, including durability follow-up at the
RP2D, are planned for presentation in the second half of 2026. Immatics is expanding clinical evaluation of IMA203CD8 into
additional PRAME-positive solid tumor indications to more fully assess its therapeutic potential.
Highlights of Immatics' clinical data
on IMA203CD8 presented at ASCO 2026
Gynecologic cancers:
Patient population: Heavily pretreated
patient population with limited treatment options
Safety: Treatment with IMA203CD8 showed
predictable and manageable tolerability
1 All patients who received IMA203CD8 infusion and had at least one post-baseline scan, progressive disease or death.
Anti-tumor activity: A one-time infusion
of IMA203CD8 PRAME cell therapy showed anti- tumor activity in gynecologic cancers at clinically relevant doses ( DL4c)
those patients who achieved a (c)CR with <100% changes from baseline, target lesions were lymph nodes that resolved to <10 mm. +
Patient had a PR prior to CR. BOR, best overall response; (c)CR: (confirmed) complete response; (c)ORR, (confirmed) objective response
rate; PD, progressive disease; (c)PR, (confirmed) partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.
2 cORR excludes one patient with ongoing unconfirmed response at data cutoff.
A one-time infusion of IMA203CD8 showed promising
anti-tumor activity with deep and durable response in synovial sarcoma across all doses (median 1.59 10 TCR T cells; range:
IMA203CD8 PRAME Cell Therapy
is Immatics' PRAME-directed TCR T-cell therapy engineered to recognize an intracellular PRAME-derived peptide presented by HLA-A*02:01
on the cell surface and initiate a potent and specific anti-tumor response. The co-transduction of CD8 alongside the PRAME
TCR adds functional CD4+ T cells designed to boost anti-tumor activity. IMA203CD8 is currently being evaluated in a Phase 1 clinical trial
in solid tumors expressing PRAME.
PRAME is a target expressed in more than 50 cancers.
Immatics is the global leader in precision targeting of PRAME and has the broadest PRAME franchise with the most PRAME indications and
modalities. The Immatics PRAME franchise currently includes three product candidates, two therapeutic modalities and three combination
therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME
bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as
anzu-cel in combination with Moderna's PRAME mRNA designed to enhance cell therapy.
Immatics is committed to making a meaningful impact
on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers.
Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities,
spanning TCR T-cell therapies and TCR bispecifics.
Immatics intends to use
its website www.immatics.com as a means of disclosing material non-public information. For regular
Forward-Looking Statements
Certain statements in
this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or the Company's
future financial or operating performance. For example, statements concerning timing of data read-outs for product candidates, observations
from the Company's clinical trials, the timing,
outcome and design of
clinical trials, the nature of clinical trials (including whether such clinical trials will be registration-enabling), the timing of IND,
CTA or BLA filings, estimated market opportunities of product candidates, the Company's focus on partnerships to advance its strategy,
and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may",
"should", "expect", "plan", "target", "intend", "will", "estimate",
"anticipate", "believe", "predict", "potential" or "continue", or the negatives
of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and
other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements.
These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management,
are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties.
Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors
beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in the Company's
Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Nothing in this press release should be
regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated
results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which
speak only as of the date they are made. The Company undertakes no duty to update these forward-looking statements. All the scientific
and clinical data presented within this press release are - by definition prior to completion of the clinical trial and a clinical
study report - preliminary in nature and subject to further quality checks including customary source data verification.
For more information, please contact:
Trophic Communications
Phone: +49 151 74416179
Phone: +1 346 319-3325